Latest news with #nonHodgkinLymphoma
E&E News
2 days ago
- Health
- E&E News
Cancer patient urges SCOTUS not to dismiss Roundup verdicts
A Missouri man who developed non-Hodgkin lymphoma after using a popular weedkiller for decades wants the Supreme Court to reject the manufacturer's request to grant it immunity from his lawsuit and thousands of others. John Durnell in a brief filed Monday says a jury found that Monsanto's Roundup caused his blood cancer and that the company is liable for damages. But, he added, the company is arguing 'as it has argued with little success for years' that it should be immune from lawsuits that it says are barred by federal law. His filing comes after Bayer in April asked the high court to determine whether the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) should invalidate thousands of lawsuits that claim the company has a duty to warn about health risks from the product. Advertisement Bayer acquired Monsanto in 2018, and the company has been inundated with what it says were 'unfounded' legal challenges across the country from customers alleging the weedkiller was responsible for their cancers.
Yahoo
30-05-2025
- Business
- Yahoo
Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas
First-in-human trial is designed to determine recommended dose of IKS03, a CD19-directed antibody drug conjugate, for the subsequent dose-expansion IKS03 is Iksuda's second asset to begin clinical testing NEWCASTLE, England, May 30, 2025--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of dosing of its first patient with IKS03, a CD19-directed ADC, in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma. This first-in-human study ( will evaluate the safety, tolerability, preliminary antineoplastic activity, pharmacokinetics and pharmacodynamics of increasing dose levels of IKS03, and determine the recommended dose for dose-expansion. Efficacy will be further evaluated in disease-specific expansion cohorts. The study is currently enrolling patients across clinical sites in Italy, Spain, Australia, United States and Canada. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: "With the first patient successfully completing the safety evaluation period with IKS03, Iksuda demonstrates its continued commitment to drive its differentiated ADCs through clinical proof of concept, further solidifying our position as a clinical-stage ADC-focused company. Although there have been advances in the treatment of non-Hodgkin lymphoma in recent years, there remains a significant unmet patient need, and we hope that IKS03 will be able to build on the potential benefit-risk profile suggested by the data generated in preclinical studies." About IKS03 IKS03 is a best-in-class CD19-targeting ADC delivering a tumour-activated prodrug pyrrolobenzodiazepine (PBD) which was licensed from LigaChem Biosciences (formerly LegoChem Biosciences) ( Preclinical testing demonstrates best-in-class efficacy (vs in-clinic and marketed CD19-targeted therapies) in in vivo xenograft models and significantly raised maximum tolerated dose (MTD) in non-human primate disease models, demonstrating its potential to be the leading anti-CD19 therapy in B-cell cancers. About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on Contacts For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive OfficerTel: +44 (0) 191 6031680Email info@ FTI Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy ByrneTel: +44 (0) 020 3727 1000Iksuda@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mail
29-05-2025
- Health
- Daily Mail
What is mantle cell lymphoma?
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma that causes white blood cells to grow and multiply uncontrollably. The average age at diagnosis is 60 to 65 years and is two to three times more common in men than women. The initial symptom of MCL is usually a painless swelling in the neck, armpit, and/or groin. It is usually treated with combination chemotherapy, but other therapies include radioimmunotherapy, radiotherapy and stem cell transplants. It is aggressive and often comes back after patients go into remission.
Fox News
22-05-2025
- Sport
- Fox News
Red Sox reliever, cancer survivor Liam Hendriks slams fans for 'vile' death threats
Boston Red Sox relief pitcher Liam Hendriks struggled in the team's 5-1 loss to the New York Mets on Wednesday at Fenway Park. Hendriks, 36, gave up three earned runs on three hits, and was charged with the loss. The reliever took to social media on Thursday morning and posted that fans were sending him and his wife death threats. "Threats against my life and my wife's life are horrible and cruel. You need help," Hendriks wrote on his Instagram story. "Leaving comments telling me to commit suicide and how you wish I died from cancer is disgusting and vile." "Maybe you should take a step back and reevaluate your life's purpose before hiding behind a screen attacking players and their families." Hendriks announced that he had been diagnosed with cancer, non-Hodgkin lymphoma, in January 2023. The three-time All-Star returned to the mound less than five months later and pitched for the Chicago White Sox. However, after just five appearances since returning to the field after his bout with cancer, Hendriks needed Tommy John surgery. The Red Sox signed him to a two-year, $10 million contract in 2024 in his recovery, but Hendriks did not pitch last season as he rehabbed. "Whether you (send death threats) from your 'fake accounts' or are you dumb enough to do it from your real account. I think I speak for all players who have to deal with this in their career when I say," Hendriks wrote. "Enough is enough." Hendriks has struggled this season with the Red Sox, as he has a 5.56 ERA in 11 games. In his 14-year career, Hendriks has a 33-35 record with a 3.85 ERA with 738 strikeouts in 661.1 career innings pitched. Follow Fox News Digital's sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.
Yahoo
22-05-2025
- Sport
- Yahoo
Red Sox reliever Liam Hendriks addresses 'horrible and cruel' threats from fans after loss to Mets
Red Sox reliever Liam Hendriks responded to the comments and threats he received on social media after Boston's loss to the New York Mets on Wednesday. Fans pinned the 5-1 defeat on Hendriks, who relieved Garrett Crochet in the sixth inning. Despite striking out two batters with the score tied at 1-1 to get out of the sixth, Hendriks gave up three straight hits without recording an out in the seventh — all of which led to the Mets piling on the lead. On Thursday, Hendriks took to Instagram to lash out at the "disgusting" response from fans. "Just as an FYI: Threats against my life and my wife's life are horrible and cruel," Hendriks wrote in an Instagram story. "You need help. Leaving comments to tell me to commit suicide and how you wish I died of cancer is disgusting and vile. "Maybe you should take a step back and reevaluate your life's purpose before hiding behind a screen attacking players and their family," he continued. "Whether you do it from your 'fake accounts' or are dumb enough to do it from your real account. I think I speak for all players who have had to deal with this in their career when I say: Enough is enough." The 14-year veteran's response alluded to him sitting out in 2024 while recovering from Tommy John surgery after his battle with non-Hodgkin lymphoma cost him most of the 2023 season. Hendriks is not the only MLB player to receive threatening messages from fans in recent weeks. Earlier this month, Astros pitcher Lance McCullers addressed fans threatening his children after a tough outing against the Cincinnati Reds. Houston police launched an investigation into the threats. McMuller's comments were in the same vein: "It's been a tough evening. I understand people are very passionate and people love the Astros and love sports, but threatening to find my kids and murder them is a little bit tough to deal with. "So, just as a father, I think there have been many, many threats over the years aimed at me mostly, and I think actually one or two people from other issues around baseball actually had to go to jail for things like that. But I think bringing kids into the equation, threatening to find them or next time they see us in public, they're gonna stab my kids to death, things like that, it's tough to hear as a dad.' Hendriks joined the Red Sox this season after stints in Minnesota, Toronto, Kansas City, Oakland and Chicago with the White Sox. Since arriving in Boston, the 36-year-old has struggled, throwing 11.1 innings with a 5.56 ERA over his 11 appearances for the Red Sox. Boston sits third in the American League East with a 25-26 record.
